START WITH CERTAINTY
Why BreastDefense?
Breast cancer unfolds over time, leaving molecular signals in the bloodstream that reflect how disease emerges and evolves long before it becomes clinically visible.
BreastDefense interprets these signals to help clinicians understand where a patient is along the path of disease and what may lie ahead.
By combining advanced molecular measurement with longitudinal data modelling, SignPost is building a biological intelligence engine that will interpret how cancer evolves within each patient.
Understanding What Lies Ahead
Breast cancer is not just a genetic battle—it is an epigenetic one, yet the diagnostic landscape has remained frozen in a reactive model that misses the very first whispers of the disease. SignPost is breaking this silence with BreastDefense, the world’s first whole-blood diagnostic tool to leverage whole-genome methylation for the comprehensive detection of both primary occurrence and reoccurrence of breast cancer.